연구업적

연구

연구
연구업적

최근 5년 연구업적 현황

연도		2023년	2022년	2021년	2020년	2019년
SCI 논문 발표편수	책임	173편	163편	184편	135편	144편
SCI 논문 발표편수	공동	120편	115편	136편	168편	167편
합계		293편	278편	320편	303편	311편

731. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading.

Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, Park JW.

Cancer Lett. 2007 Sep 18;255(1):107-16. Epub 2007 May 14 Link

730. CITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition.

Shin DH, Li SH, Chun YS, Huang LE, Kim MS, Park JW.

Oncogene. 2007 Oct 1 Link

729. ATP6V0C competes with von Hippel-Lindau protein in hypoxia-inducible factor 1alpha (HIF-1alpha) binding and mediates HIF-1alpha expression by bafilomycin A1.

Lim JH, Park JW, Kim SJ, Kim MS, Park SK, Johnson RS, Chun YS.

Mol Pharmacol. 2007 Mar;71(3):942-8. Epub 2006 Dec 18 Link

728. HIF-1alpha promotes survival of prostate cells at a high zinc environment.

Park SE, ParK JW, Cho YS, Ryu JH, Paick JS, Chun YS,

Prostate.2007Oct 1;67(14):1514-23 Link

727. Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.

Lee KW, Kim JH, Yun T, Song EK, Na II, Shin H, Oh SY, Choi IS, Oh do Y, Kim DW, Im SA, Kim TY, Lee JS, Heo DS, Bang YJ, Kim NK.

J Korean Med Sci. 2007 Sep;22 Suppl:S115-21 Link

726. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.

Han SW, Jeon YK, Lee KH, Keam B, Hwang PG, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY.

Pharmacogenet Genomics. 2007 May;17(5):313-9 Link

725. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.

Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, Kim TY.

J Mol Med. 2007 Oct;85(10):1137-48. Link

724. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.

Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.

Lung Cancer. 2007 Nov 22 Link

723. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63. Link

722. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Nov 1;7(1):203 Link